Acta Vet. Brno 2006, 75: 515-522

Therapeutic Effects of Enrofloxacin in Mastitis-metritis-agalactia Syndrome: A Review

Z. Valenčak1, M. Štukelj, L. Ščuka2

1Veterinary Faculty, University of Ljubljana, Slovenia
2Krka d.d., Novo Mesto, Slovenia

Received January 3, 2005
Accepted September 5, 2006

The efficacy of enrofloxacin in the mastitis-metritis-agalactia (MMA)-syndrome was inspected by necessary clinical trials and by using a meta-analysis or systematic review. Numerous aetiologies or pathophysiologies can be involved in the MMA-syndrome. Fever, anorexia, vulva discharge and mastitis are the basic changes but the growth rate and survival of the litter are the main problem of MMA. Our survey included 6 studies, of which four were entered in the meta-analysis itself; two studies dealt with the susceptibility profile of bacteria to enrofloxacin. As evident from the meta-analysis, enrofloxacin was effective in the treatment of the MMA-syndrome in pigs. Out of all studies, the results were statistically significant (p < 0.05) in three of them, whereas the overall result of metaanalysis indicates a high efficacy of enrofloxacin (p = 0.002) in treatment of the MMA syndrome. In total, there were not more than 0.3% of less susceptible and non-resistant strains out of all surveyed strains E. coli (n = 295) within MMA-sydrome and the MIC value for E. coli ranged between 0.03 and 0.06 μg/ml. The high efficacy of enrofloxacin in the MMA-syndrome therapy has been confirmed by meta-analysis and systematic review.